Acadia Pharmaceuticals (ACAD) Stock
Biotech firm with approved Parkinson's disease psychosis treatment. Here's the price, business snapshot, and what's worth knowing about Acadia Pharmaceuticals in September 2026.
ACADIA Pharmaceuticals (ACAD) is a clinical-stage biopharmaceutical company focused on disorders of the central nervous system. It is best known for pimavanserin (marketed as Nuplazid in some regions), approved for Parkinson's disease psychosis, and is developing additional indications and programmes in dementia-related psychosis and other neuropsychiatric conditions. Revenue to date has been largely driven by its lead product while the company advances clinical trials and potential label expansions. Investors should be aware that ACADIA’s value is sensitive to binary clinical and regulatory outcomes, patent and exclusivity timelines, and commercial execution. With a market capitalisation around $3.6bn, it sits in the small‑to‑mid cap biotech range and can show higher volatility than large diversified healthcare firms. This summary is for general educational purposes only and not personalised advice; biotech investments carry both upside potential and significant downside risk, and past performance is not indicative of future results.
Why You’ll Want to Watch This Stock
CNS-focused pipeline
ACADIA centres on neuropsychiatric and neurodegenerative indications; successful trials could change the investment case, though outcomes are uncertain.
Single-product reliance
Revenue has depended largely on pimavanserin, so commercial performance and patent timelines are key considerations for investors.
Regulatory catalysts ahead
Upcoming trial readouts and regulator decisions can create material share-price moves — both positive and negative — so monitor news and filings closely.
